AIM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:57):

Stats
Dzisiejszy wolumen	116 604
Średni wolumen	236 640
Kapitalizacja rynkowa	20.17M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $-0.120 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.670
ATR14	$0.00600 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-30	Rodino Peter W Iii	Buy	100 000	Options
2023-11-30	Equels Thomas K	Buy	300 000	Options
2024-03-21	Bryan Nancy	Buy	38 462	Common Stock
2024-03-15	Appelrouth Stewart	Buy	90 910	Common Stock
2024-03-15	Equels Thomas K	Buy	75 758	Common Stock

INSIDER POWER
89.44
Last 98 transactions
Buy: 4 006 121 \| Sell: 118 208

Wolumen Korelacja

Długi: -0.11 (neutral)

Krótki: -0.17 (neutral)

Signal:(53.983) Neutral

AIM ImmunoTech Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AIM ImmunoTech Inc Korelacja - Waluta/Towar

0.53
( weak )

0.51
( weak )

0.00
( neutral )

0.09
( neutral )

AIM ImmunoTech Inc Finanse

Annual	2023
Przychody:	$202 000
Zysk brutto:	$-78 000.00 (-38.61 %)
EPS:	$-0.600

FY	2023
Przychody:	$202 000
Zysk brutto:	$-78 000.00 (-38.61 %)
EPS:	$-0.600

FY	2022
Przychody:	$141 000
Zysk brutto:	$-19.78M (-14 029.79 %)
EPS:	$-0.440

FY	2021
Przychody:	$135 000
Zysk brutto:	$-715 000 (-529.63 %)
EPS:	$-0.400

Financial Reports:

No articles found.

AIM ImmunoTech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.